TY - JOUR
T1 - Convalescent plasma in Covid-19
T2 - Possible mechanisms of action
AU - Rojas, Manuel
AU - Rodríguez, Yhojan
AU - Monsalve, Diana M.
AU - Acosta-Ampudia, Yeny
AU - Camacho, Bernardo
AU - Gallo, Juan Esteban
AU - Rojas-Villarraga, Adriana
AU - Ramírez-Santana, Carolina
AU - Díaz-Coronado, Juan C.
AU - Manrique, Rubén
AU - Mantilla, Ruben D.
AU - Shoenfeld, Yehuda
AU - Anaya, Juan Manuel
N1 - Funding Information:
This work was supported by Universidad del Rosario ( ABN-011 ), Bogota, and Universidad CES (Office of Research and Innovation) , Medellin, Colombia.
Publisher Copyright:
© 2020 The Author(s)
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the possible mechanisms of action of CP and their repercussion in COVID-19 pathogenesis, including direct neutralization of the virus, control of an overactive immune system (i.e., cytokine storm, Th1/Th17 ratio, complement activation) and immunomodulation of a hypercoagulable state. All these benefits of CP are expected to be better achieved if used in non-critically hospitalized patients, in the hope of reducing morbidity and mortality.
UR - http://www.scopus.com/inward/record.url?scp=85084510800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084510800&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2020.102554
DO - 10.1016/j.autrev.2020.102554
M3 - Review article
C2 - 32380316
AN - SCOPUS:85084510800
SN - 1568-9972
VL - 19
SP - 102554
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 7
M1 - 102554
ER -
